National Association for Continuing Education

COPD: New Developments, New Treatment Horizons

Final Outcome Report

Challenges in Pulmonary and Critical Care: 2012

Presented at:
Cleveland Clinic Florida
Weston, Florida
December 1, 2012

Report Date: May 2, 2013
Course Director

Franck Rahaghi, MD, MHS, FCCP
Director, Pulmonary Hypertension Clinic
Director, Pulmonary Education and Rehabilitation
Chair of Quality
Cleveland Clinic Florida
Weston, FL

Course Accreditation

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of University of Massachusetts Medical School and the National Association for Continuing Education. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The University of Massachusetts Medical School designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support

Challenges in Pulmonary and Critical Care: 2012 CME activity was supported through educational grants or donations from the following companies:

Actellion
Baxter
Boehringer Ingelheim Pharmaceuticals, Inc.
Boston Scientific
CSL Behring
Genentech
Grifols
Hospira, Inc.
United Therapeutics Corporation
7:15-7:50  Continental Breakfast and Registration

7:50-8:00  Welcome Remarks
Franck Rahaghi, MD, MHS, FCCP

8:00-9:00  Electromagnetic Navigation Bronchoscopy and Bronchial Thermoplasty: Two Techniques That Are Revolutionizing Bronchoscopy
Eduardo Oliveira, MD, MBA

8:00-10:00  COPD: New Developments, New Treatment Horizons
Charlie Strange, MD

9:00-10:00  COPD: New Developments, New Treatment Horizons
Charlie Strange, MD

10:00-10:15  Break/Exhibits

10:15-11:15  Alpha-1 Antitrypsin Deficiency: How to Change
Franck Rahaghi, MD, MHS, FCCP

11:15-12:15  Pulmonary Hypertension: A Disease Evolution
Ioana Preston, MD

12:15-1:00  Lunch Break/Exhibits

12:15-2:00  Idiopathic Pulmonary Fibrosis: Updates from IPFNET and New Horizons
Robert Kaner, MD

1:00-2:00  Idiopathic Pulmonary Fibrosis: Updates from IPFNET and New Horizons
Robert Kaner, MD

2:00-3:00  New Directions in Treatment of Asthma
Raed A. Dweik, MD

3:00-3:15  Break/Exhibits

3:15-4:15  Sedation in the ICU
Jinesh Mehta, MD

4:15-5:30  Management of Chronic Cough
Gustavo Ferrer, MD

5:15-5:30  Closing Remarks
Franck Rahaghi, MD, MHS, FCCP
Levels of Evaluation

Consistent with the policies of the ACCME, NACE evaluates the effectiveness of all CME activities using a systematic process based on the following model:

1. Participation
2. Satisfaction
3. Learning
   A. Declarative Knowledge
   B. Procedural Knowledge
4. Competence
5. Performance
6. Patient Health
7. Community Health

Level 1: Participation

- 122 attendees
- 61% Physicians; 8% NPs; 5% PAs; 7% RNs; 19% Other
- Over 40% in community-based practice
- 37% PCPs, 40% Pulmonologists; 3% Rheumatology; 3% Cardiologists; 17% Other or did not respond

Did we reach the right audience? Yes!
Level 2: Satisfaction

• 100% rated the activity as very good to excellent
• 98% indicated the activity improved their knowledge
• 98% stated that they learned new strategies for patient care
• 85% said they would implement new strategies that they learned in their practice
• 100% said the program was fair-balanced and unbiased

Were our learners satisfied? Yes!
Level 2: Satisfaction

Upon completion of this activity, I can now –
Explain the pathogenesis and diagnosis of COPD; Discuss findings of recent trials and evidence-based treatment options for COPD; Discuss new GOLD guidelines; Explore new and evolving treatments for COPD:

Did learners indicate they achieved the learning objectives?
Yes! 100% believed they did.
Outcome Study Methodology

Goal
To determine the effect this CME activity had on learners with respect to competence to apply critical knowledge, confidence in treating patients with diseases or conditions discussed, and change in practice behavior.

Dependent Variables

1. **Level 3-5: Knowledge, Competence, and Performance**
   Case-based vignettes and pre- and post-test knowledge questions were asked with each session in the CME activity. Identical questions were also asked to a sample of attendees 4 weeks after the program to assess retention of knowledge. Responses can demonstrate learning and competence in applying critical knowledge. The use of case vignettes for this purpose has considerable predictive value. Vignettes, or written case simulations, have been widely used as indicators of actual practice behavior. ¹

2. **Practitioner Confidence**
   Confidence with the information relates directly to the likeliness of actively using knowledge. Practitioner confidence in his/her ability to diagnose and treat a disease or condition can affect practice behavior patterns.

3. **Level 5: Self-Reported Change in Practice Behavior**
   Four weeks after CME activity, practitioners are asked if they changed practice behavior.

4. Readiness to Change Behavior (Prochaska and DeClemente Model)

CME activities can motivate providers to move through different stages of change which can ultimately lead them to take action and modify their practice behavior in accordance with the objectives of the education. Movement through these stages of change is an important dependent variable to consider in evaluating the impact of CME. Participants were asked to evaluate their stage of change with respect to specific topics being presented.

- **Pre-contemplation stage**: I do not manage (XXX illness), nor do I plan to this year.
- **Contemplation stage**: I did not manage (XXX illness) before this course, but as a result of attending this course I'm thinking of managing it now.
- **Pre-contemplation/confirmation stage**: I do manage patients with (XXX Illness) and this course confirmed that I do not need to change my treatment methods.
- **Preparation for action stage**: I do manage patients with (XXX illness) and this course helped me change my treatment methods.

COPD: New Developments, New Treatment Horizons

Faculty
Charlie Strange, MD
Professor of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, SC

Learning Objectives

• Explain the pathogenesis and diagnosis of COPD
• Discuss findings of recent trials and evidence-based treatment options for COPD
• Discuss new GOLD guidelines; Explore new and evolving treatments for COPD
### Key Findings
COPD: New Developments, New Treatment Horizons

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knowledge/Competence</td>
<td>Learners demonstrated improvements in their answers from pre to post-testing on two of the three case-based questions regarding COPD.</td>
</tr>
<tr>
<td>Confidence</td>
<td>Whereas the majority of learners rated themselves as having moderate confidence in their understanding of treating COPD before the education most of the learners showed very high gains in confidence after the program.</td>
</tr>
<tr>
<td>Intent to Perform</td>
<td>As a result of this program, 6% of learners who did not manage COPD before are considering doing so, while 58% indicated that they will change their treatment methods.</td>
</tr>
<tr>
<td>Change of Practice Behavior</td>
<td>100% of learners who responded to our four week survey indicated that they had changed their practice behavior to implement the learning objectives of this program within four weeks after they attended the activity.</td>
</tr>
</tbody>
</table>

N=57
JW is a 60 year old female who had asthma throughout her childhood years. She ran track in college but noted that after her first pregnancy she had a slowly progressive cough that never completely left her. She smoked for only a few years after college. Her cough gets worse with colds and airway irritants when she has heard wheezing. It gets a little better with an albuterol inhaler before exercise that she rarely does anymore. Which is a true statement about JW?

Red highlight indicates no significant difference between pre and post testing.
Case Vignette Knowledge and Competence Assessment Questions
(Presented before and after lecture. Boxed answer is correct.)

ATS/ERS recommend Alpha-1 Testing In Chronic Obstructive Pulmonary Disease (COPD)

Exacerbations are associated with poor quality of life.
Exacerbations are a leading cause of ER visits and hospitalizations.
Exacerbation reduction by daily preventive medications is a cost effective treatment strategy.
Mucolytic medications are effective for COPD exacerbations.

N = 67

Green highlight indicates significant difference between pre and post testing.

P Value: <0.001 - Significant
Case Vignette Knowledge and Competence Assessment Questions
(Presented before and after lecture. Boxed answer is correct.)

JJ is a 65 yo. and has smoked for 40 yrs -FVC 70% -FEV1 40% no BR -Ratio 0.57 No point in testing him since as a smoker, even if he is positive, he would not get replacement therapy

Red highlight indicates no significant difference between pre and post testing.
Change in Practice Behavior Question
Presented after lecture.

Which of the statements below describes your approach to anticoagulation of patients with COPD?

- Pre-Contemplation Stage: I do not treat COPD, nor do I plan to this year. 12%
- Contemplation Stage: I did not treat COPD before this course, but as a result of attending this course I’m thinking of treating it now. 6%
- Preparation for Action Stage: I do treat COPD and this course helped me change my treatment methods. 58%
- Pre-Contemplation/Confirmation Stage: I do treat COPD and this course confirmed that I don't need to change my treatment methods. 24%
Changes in Confidence from Pre to Post-Testing
COPD: New Developments, New Treatment Horizons

On a scale of 1 to 5 please rate how confident you would be in treating patients with this condition.

N = 72

<table>
<thead>
<tr>
<th>Rating</th>
<th>Pre %</th>
<th>Post %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not at all confident</td>
<td>7%</td>
<td>2%</td>
</tr>
<tr>
<td>Slightly confident</td>
<td>14%</td>
<td>5%</td>
</tr>
<tr>
<td>Moderately confident</td>
<td>25%</td>
<td>17%</td>
</tr>
<tr>
<td>Pretty much confident</td>
<td>31%</td>
<td>32%</td>
</tr>
<tr>
<td>Very confident</td>
<td>24%</td>
<td>44%</td>
</tr>
</tbody>
</table>
Intention to Change Practice Behavior and Implement Learning

- Very likely: 64%
- Somewhat likely: 21%
- Unlikely: 2%
- Not applicable: 13%

N = 165
Discussion and Implications
COPD: New Developments, New Treatment Horizons

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity, mortality, and disability. COPD is underdiagnosed and its management is suboptimal. The need for continued education in the area of COPD was stated in a comprehensive needs assessment and gap analysis completed prior to the activity. Planners sought to help primary care providers and pulmonologists attending this activity better explain the pathogenesis and diagnosis of COPD, discuss findings of recent trials and evidence-based treatment options for COPD, discuss new GOLD guidelines, and explore new and evolving treatments for COPD.

Knowledge/Competence: Attendee knowledge was assessed at two points for this activity: prior to the activity and immediately following the activity using the case vignettes and knowledge questions listed earlier. The results indicated improvement in knowledge as measured by positive changes in pre to post-test scores on two of the three questions asked.

Readiness to Change: Fifty-eight percent of attendees noted that they currently treat patients with COPD and that this activity provided information that would lead to further changes in their care of patients with COPD. Only six percent indicated that they did not treat patients with COPD prior to this activity, but would consider doing so after having been exposed to the information taught.

Confidence: Participants indicated a strong overall increase in self-reported confidence levels in treating patients with COPD. Attendees who reported that they felt very confident rose from 24% to 44% by the end of the program.

Intention for Change in Practice Behavior: Sixty-four percent of participants reported that they were very likely to utilize information learned from this activity in their practice.

Summary: This activity was successful in the goal of improving understanding of COPD to attendees and had a positive impact in terms of self-reported likelihood of practice change. Based on the data collected at this educational activity, there appears to be a need for further education on this topic.